Quest Diagnostics Inc (DGX): Everett Cunningham , SVP, Commercial of Quest Diagnostics Inc sold 56,312 shares on May 9, 2016. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $76.24 per share for a total value of $4,294,396.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 9, 2016, Everett Cunningham (SVP, Commercial) sold 50,447 shares at $76.00 per share price.On Apr 27, 2016, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 29,550 shares at $74.43 per share price.Also, On Mar 3, 2016, Michael E Prevoznik (SVP & General Counsel) sold 3,815 shares at $68.40 per share price.On Aug 13, 2015, John C Md Baldwin (director) sold 2,266 shares at $72.00 per share price.
Shares of Quest Diagnostics Inc (DGX) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -0.30% at $76.31 with 8,04,801 shares getting traded. Post opening the session at $76.65, the shares hit an intraday low of $75.62 and an intraday high of $76.65 and the price vacillated in this range throughout the day. The company has a market cap of $10,795 M and the number of outstanding shares has been calculated to be 14,14,57,180 shares. The 52-week high of Quest Diagnostics Inc is $89 and the 52-week low is $59.655.
Company has been under the radar of several Street Analysts.Quest Diagnostics Inc is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 76 from a previous price target of $70 .The Rating was issued on Apr 22, 2016.Quest Diagnostics Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $72 .The Rating was issued on Apr 22, 2016.Quest Diagnostics Inc is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 84 from a previous price target of $75 .The Rating was issued on Apr 21, 2016.Quest Diagnostics Inc is Initiated by Credit Suisse to Neutral. The Rating was issued on Mar 16, 2016.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.